Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2017 Sep 4;18(1):411.
doi: 10.1186/s13063-017-2157-3.

Effect of maternal vitamin D3 supplementation on maternal health, birth outcomes, and infant growth among HIV-infected Tanzanian pregnant women: study protocol for a randomized controlled trial

Christopher R Sudfeld  1 , Karim P Manji  2   3 , Christopher P Duggan  4   5   6 , Said Aboud  7   3 , Alfa Muhihi  3 , David M Sando  4   3 , Fadhlun M Alwy Al-Beity  8   3 , Molin Wang  9 , Wafaie W Fawzi  4   10   5
Affiliations
Randomized Controlled Trial

Effect of maternal vitamin D3 supplementation on maternal health, birth outcomes, and infant growth among HIV-infected Tanzanian pregnant women: study protocol for a randomized controlled trial

Christopher R Sudfeld et al. Trials. .

Abstract

Background: Vitamin D has significant immunomodulatory effects on both adaptive and innate immune responses. Observational studies indicate that adults infected with HIV with low vitamin D status may be at increased risk of mortality, pulmonary tuberculosis, and HIV disease progression. Growing observational evidence also suggests that low vitamin D status in pregnancy may increase the risk of adverse birth and infant health outcomes. As a result, antiretroviral therapy (ART) adjunct vitamin D3 supplementation may improve the health of HIV-infected pregnant women and their children.

Methods/design: The Trial of Vitamins-5 (ToV5) is an individually randomized, double-blind, placebo-controlled trial of maternal vitamin D3 (cholecalciferol) supplementation conducted among 2300 HIV-infected pregnant women receiving triple-drug ART under Option B+ in Dar es Salaam, Tanzania. HIV-infected pregnant women of 12-27 weeks gestation are randomized to either: 1) 3000 IU vitamin D3 taken daily from randomization in pregnancy until trial discharge at 12 months postpartum; or 2) a matching placebo regimen. Maternal participants are followed-up at monthly clinic visits during pregnancy, at delivery, and then with their children at monthly postpartum clinic visits. The primary efficacy outcomes of the trial are: 1) maternal HIV disease progression or death; 2) risk of small-for-gestational age (SGA) births; and 3) risk of infant stunting at 1 year of age. The primary safety outcome of the trial is incident maternal hypercalcemia. Secondary outcomes include a range of clinical and biological maternal and child health outcomes.

Discussion: The ToV5 will provide causal evidence on the effect of vitamin D3 supplementation on HIV progression and death, SGA births, and infant stunting at 1 year of age. The results of the trial are likely generalizable to HIV-infected pregnant women and their children in similar resource-limited settings utilizing the Option B+ approach.

Trial registration: ClinicalTrials.gov identifier: NCT02305927 . Registered on 29 October 2014.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

The ToV5 protocol was approved by the Harvard T.H. Chan School of Public Health Institutional Review Board (reference no. IRB14-3416), the Tanzanian National Health Research Ethics Sub-Committee (NatHREC; reference no. NIMR/HQ/R.8a/Vol.IX/1933), and the Tanzania Food and Drug Authority (TFDA; reference no. TFDA15/CTR/0003/5). All participants will provide written informed consent for both screening and trial enrollment. Individuals who consent for trial enrollment are also asked for consent to escort the participant home to register the address, to contact the participant, neighbors, or relatives by cell phone or a home visit if the participant misses a clinic visit, and to store and use of all data and maternal and child blood samples for future research studies.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
The Trial of Vitamins-5 (ToV5) flow diagram
Fig. 2
Fig. 2
Schedule of enrollment, interventions, and assessments (SPIRIT Figure). 25(OH)D 25-hydroxyvitamin D, HIV human immunodeficiency virus, MUAC mid-upper arm circumference, WHO World Health Organization
See this image and copyright information in PMC

References

    1. Cooper ER, Charurat M, Mofenson L, Hanson IC, Pitt J, Diaz C, Hayani K, Handelsman E, Smeriglio V, Hoff R, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr. 2002;29(5):484–94. doi: 10.1097/00042560-200204150-00009. - DOI - PubMed
    1. World Health Organization . Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. Geneva, Switzerland: World Health Organization; 2015. - PubMed
    1. World Health Organization . Consolidated guidelines on general HIV care and the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva, Switzerland: World Health Organization; 2013.
    1. Centers for Disease Control and Prevention Impact of an innovative approach to prevent mother-to-child transmission of HIV—Malawi, July 2011–September 2012. MMWR Morb Mortal Wkly Rep. 2013;62(8):148. - PMC - PubMed
    1. UNAIDS . Global plan towards the elimination of new HIV infections among children by 2015. Geneva, Switzerland: UNAIDS; 2011. - PubMed

Publication types

MeSH terms

Associated data